Cowen and Company’s Ultragenyx Pharmaceutical RARE Stock Holding History

Cowen and Company’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,756	Closed	-$263K	–	683
2021 Q2	$263K	Buy	+2,756	New	+$287K	0.01%	244

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Cowen and Company's RARE Position: Q3 2021 in Review

Cowen and Company sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2021, closing a stake of 2,756 shares — an estimated $263K sold.

Cowen and Company first reported a position in RARE in Q2 2021 and held it in 1 quarter. The position peaked at $263K in Q2 2021. 221 funds tracked by Wall St. Rank hold RARE as of Q3 2021.

Cowen and Company reported no remaining Ultragenyx Pharmaceutical position as of Q3 2021 after selling out during the quarter.
Cowen and Company sold 2,756 Ultragenyx Pharmaceutical shares in Q3 2021, an estimated $263K.
Cowen and Company first reported a position in Ultragenyx Pharmaceutical in Q2 2021 and held it in 1 quarter.
Cowen and Company's Ultragenyx Pharmaceutical position peaked at $263K in Q2 2021.
221 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2021.

Based on Cowen and Company's 13F filing for Q3 2021, filed 12 Nov 2021.